共 71 条
[1]
Eikelboom JW(2017)Laboratory monitoring of non–vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation JAMA Cardiol 2 566-1020
[2]
Quinlan DJ(2021)2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants Thromb Haemost 121 1008-450
[3]
Hirsh J(2018)International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants Thromb Haemost 118 437-848
[4]
Douxfils J(2018)Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants J Thromb Haemost 16 842-879
[5]
Adcock DM(2019)Cerebral ischemia in patients on direct oral anticoagulants Stroke 50 873-760
[6]
Bates SM(2013)Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis J Thromb Haemost 11 756-13
[7]
Gosselin R(2015)Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations Biomed Res Int 2015 1-1327
[8]
Adcock D(2016)To measure or not to measure direct oral anticoagulants before surgery or invasive procedures J Thromb Haemost 14 1325-1676
[9]
Bates S(2021)2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation EP Eur 23 1612-101
[10]
Testa S(2019)Stroke-related epilepsy Eur J Neurol 26 18-2427